Tolvaptan for treating autosomal dominant polycystic kidney disease

  • Technology appraisal guidance
  • TA358
  • Published: 
Download guidance (PDF)

1 Guidance

1.1 Tolvaptan is recommended as an option for treating autosomal dominant polycystic kidney disease in adults to slow the progression of cyst development and renal insufficiency only if:

  • they have chronic kidney disease stage 2 or 3 at the start of treatment

  • there is evidence of rapidly progressing disease and

  • the company provides it with the discount agreed in the patient access scheme.

1.2 People whose treatment with tolvaptan is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)